Regular rituximab treatment in neuromyelitis optica spectrum disorder resulted in less disability and fewer relapses, per a real word study.| Neuromyelitis News
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
Rituximab safely and effectively treated sudden interstitial lung disease in a man with undiagnosed primary Sjögren’s syndrome.| Sjogren's Syndrome News
Rituximab isn't officially approved for MG, but is used off-label when standard treatments fail, such as patients with anti-MuSK antibodies.| Myasthenia Gravis News
Rituximab was more efficient at preventing relapses than oral immunosuppressive therapies in a racially diverse group of people with NMOSD.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News